BioSig Technologies Announces PURE-EP System Clinical Data

BioSig Technologies, Inc. announced that clinical data from the company’s PURE EP System, a biomedical signal processing platform designed to improve the efficacy and efficiency of ablation procedures, will be featured in two presentations (abstracts) at the annual Heart Rhythm 2021 convention

The first presentation was co-authored by Pedram Kazemian, M.D. et al., of Deborah Heart and Lung Center in Browns Mills, New Jersey, is titled, “Post-Ablation Bipolar Voltage By PURE EP(tm) As a Marker Of Transmural Lesion.”

The second abstract was co-authored by Jonathan Salas, B.S.; Pasquale Santangeli, M.D.; David Callans, M.D.; Francis E. Marchlinski, M.D.; Cory M. Tschabrunn, Ph.D. of University of Pennsylvania in Philadelphia, Pennsylvania, is titled, “Atrial Unipolar Electrogram Filtering to Better Delineate EGM Amplitude and Morphology During Radiofrequency Ablation.”
BioSig’s PURE EP System is designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals during complex ablation procedures.
The company completed enrollment for its second multi-center clinical trial in April 2021 and looks forward to sharing PURE EP’s most recent clinical data in-person at the Heart Rhythm 2021 convention on July 28-31, 2021.

Hot this week

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”

Avery Dennison Medical Introduces Ipdated SilFoam Lite: Sustainability, MDR Certification & Performance Improvements

The newly enhanced SilFoam Lite delivers superior efficiency and reliability, bringing improved fluid handling capabilities and improved tack. These improvements make the product ideal for customers seeking quality, high-performance solutions in wound care notes Avery Dennison Medical.

Voluntary Recall Notifying Medtronic Insulin Pump Users of Potential Risks of Shortened Pump Battery Life

Medtronic plc voluntarily issued a field action starting on July 31, 2024, notifying global customers of its MiniMed™ 600 series or 700 series insulin pumps to follow their pump's built-in alerts and alarms for battery status and to contact Medtronic if they observe changes in the battery life of their pump

Medtronic Expands AiBLE Spine Surgery Ecosystem with New Technologies and Siemens Healthineers Partnership

New advancements in the AiBLE Spine Surgery ecosystem build upon the company's commitment to procedural innovation and execution